AbbVie reported that its immunology drugs Skyrizi and Rinvoq contributed significantly to its 2025 sales, with the company’s immunology portfolio generating nearly half of its total $61.1 billion in revenue. Skyrizi brought in $17.5 billion, Rinvoq $8.3 billion, and Humira, despite declining sales, added another $4.5 billion.
While these numbers highlight the strength of AbbVie’s immunology business—which grew by 18.3%—executives continued to stress the importance of other areas such as neuroscience and oncology. CEO Robert Michael stated during the company’s fourth-quarter and full-year earnings call, “Beyond immunology, when you look at AbbVie, I think what’s underappreciated is both neuroscience and oncology.” He reiterated this point from previous comments made at the J.P. Morgan Healthcare conference.
Michael pointed out Vyalev, a Parkinson’s disease treatment approved in late 2024, as a key product in their emerging neuroscience portfolio. The drug saw a 33% increase in sales during the fourth quarter, reaching $183 million for that period and totaling $482 million for the year. “We are very excited for our emerging portfolio in Parkinson’s disease, which we believe remains underappreciated,” Michael said.
AbbVie also aims to expand into oncology and obesity treatments. During its presentation at the J.P. Morgan conference, the company announced a licensing deal with China-based RemeGen to enter the PD-1/VEGF space in cancer therapy.
The company is conducting Phase I studies for ABBV295, an amylin analog acquired through a deal with Gubra last year. Results are expected later this year as AbbVie looks to further diversify into obesity treatments. Michael commented on future acquisitions: “We’re clearly taking a close look at what’s available out there, and if we see something that we feel is differentiated, we’ll pursue it… We certainly have financial wherewithal strategically for the company.”
Despite efforts to shift focus toward new therapeutic areas, much of the discussion remained on Skyrizi and Rinvoq as they surpass Humira's peak sales after eight years on the market—a development Michael called “remarkable.” Both drugs treat conditions such as ulcerative colitis and Crohn’s disease.
Executives addressed concerns about competition from Johnson & Johnson’s Tremfya—another IL-23-based drug approved for similar indications including Crohn's disease—as it gains traction in inflammatory diseases. Chief Commercial Officer Jeffrey Stewart stated: “Our compete level is extremely high,” referring to AbbVie’s position in immunology markets. He added: “and we’re very, very comfortable with the momentum that we’re going to continue to see with Skyrizi.”
